Interpretation of the clinical practice guideline for treatment of rapidly progressive autosomal dominant polycystic kidney disease with tolvaptan

PDF(1760 KB)
Chinese Journal of Nephrology
Chinese Journal of Nephrology ›› 2019, Vol. 35 ›› Issue (5) : 387-392. DOI: 10.3760/cma.j.issn.1001-7097.2019.05.011

Interpretation of the clinical practice guideline for treatment of rapidly progressive autosomal dominant polycystic kidney disease with tolvaptan

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2019, 35(5): 387-392. DOI: 10.3760/cma.j.issn.1001-7097.2019.05.011.

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(1760 KB)

Accesses

Citation

Detail
Sections
Recommended

Copyright© by the Editorial Board of Chinese Journal of Nephrology, Chinese Medical Association and the First Affiliated Hospital of Sun Yat-sen University (Guangzhou) Journal Co., Ltd

Address: Floor 2, Longzhu building, No. 5, Zhusigang Second Road, Yuexiu District, Guangzhou (510080) Tel：(020)87331532　Email：cmaszb@mail.sysu.edu.cn

This system is designed and developed by Beijing magtec Technology Development Co., Ltd. with technical support: support@magtech.com.cn

粤ICP备10090623号

/

〈 〉